Immunotherapy Rechallenge After Checkpoint Inhibitor Induced Hemophagocytic Lymphohistiocytosis: A Case Report and Literature Review

IF 3.3 3区医学 Q2 ONCOLOGY

Clinical colorectal cancer Pub Date : 2024-06-01 DOI:10.1016/j.clcc.2024.01.005

Dorien Geusens , Daan Dierickx , Saskia Carton , Eric Van Cutsem , Jeroen Dekervel

引用次数: 0

Abstract

•
As there are increasingly more indications for immune checkpoint inhibitors (ICI), immune related adverse events will also become more prevalent. ICI induced haemophagocytic lymphohistiocytosis (HLH) has been described in case reports and pharmacovigilance database reviews. Literature regarding rechallenge of ICI after resolution of HLH is limited to a few cases.
•
With this case report, we want to highlight the need for early diagnosis and treatment. We also showed that ICI may be rechallenged safely, provided close monitoring and discussion with the patient.
•
This article might impact on clinical practice by increasing awareness about ICI induced HLH and contributing to the body of literature regarding this topic.

查看原文本刊更多论文

检查点抑制剂诱发嗜血细胞淋巴组织细胞增多症后的免疫疗法再挑战：病例报告与文献综述

免疫检查点抑制剂（ICI）在（结直肠）癌的治疗中正变得越来越重要。嗜血细胞性淋巴组织细胞增多症（HLH）涉及免疫过度激活，是免疫疗法的一种罕见但危及生命的不良反应，而且难以诊断。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical colorectal cancer 医学-肿瘤学

CiteScore

5.50

自引率

2.90%

发文量

审稿时长

27 days

期刊介绍： Clinical Colorectal Cancer is a peer-reviewed, quarterly journal that publishes original articles describing various aspects of clinical and translational research of gastrointestinal cancers. Clinical Colorectal Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of colorectal, pancreatic, liver, and other gastrointestinal cancers. The main emphasis is on recent scientific developments in all areas related to gastrointestinal cancers. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.